Company Profile

Ibris Inc
Profile last edited on: 8/3/2018

Predicting breast cancer aggressiveness
Year Founded
2010
First SBIR Year
2011
Latest SBIR Award
2011
Program Status
Inactive (Acquired)

WikiProfile

Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

307 Margaret Court
South Plainfield, NJ 07080
   (732) 993-4208
   N/A
   www.ibrisinc.com
Multiple Locations:   
Congressional District:   06
County:   Middlesx

Public Profile

With early ties to Rutgers University, I Inspirata, Inc. was acquired Inspira in 2015. Patients with aggressive estrogen receptor-positive breast cancer need chemotherapy in addition to treatment with anti-estrogen therapies. The question for physicians: how to determine how aggressive a cancer is going to be? Ibris Inc. is working to provide that information with a rapid, predictive, prognostic test that can identify ER-positive breast cancer patients requiring chemotherapy. Ibris Inc had been developing technology designed to predict how aggressive a common form of breast cancer is likely to be, helping physicians and patients plan effective therapies that minimize side effects.Ibris can target ER positive breast cancer, Inspirata is a medical imaging company applying their PathologyNEXTTM plan to advance the practice of pathology with digital pathology solutions. These solutions utilize 21st century tools and technologies to increase the speed of cancer detection, diagnosis, and treatment.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
1-4
Revenue Range
Less than .5M
VC funded?
No
Public/Private
Privately Held
Stock Info
---
IP Holdings
N/A

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount Project Title
1 NIH $207,067
Decision Support System For Predicting Outcome Of Er+ Breast Cancers

Key People / Management

  James Monaco -- President

  Dave Harding --

  Annat Madabushi --